文献速递慢性肾脏病遗传性与小管间质肾病

国际队列研究:五十年间肾病型胱氨酸病结局分析

An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.
PubMed 文献 · Kidney Int · 2021-07-06

该研究纳入1964至2016年间在九国随访的453例肾病型胱氨酸病患者,分析肾脏和生长结局相关因素。结果显示,从1970年代至1990年代,肾脏生存期中位数提高9.1年,早期启动胱氨酸消耗剂治疗及较低白细胞胱氨酸水平与更好的肾脏和生长结局相关。

要点

  • 早期启动胱氨酸消耗剂治疗与延缓终末期肾病进展相关。
  • 较高的平均白细胞胱氨酸水平是早期进展至终末期肾病的显著危险因素。
  • 性别、CTNS基因致病变异、吲哚美辛或RAS阻滞剂对肾功能无显著影响。

核心结论

  • 早期诊断和优化胱氨酸消耗治疗对肾病型胱氨酸病患者具有明确获益。

研究设计与样本

  • 国际多中心队列研究,纳入1964至2016年出生、在比利时、德国、奥地利、法国、意大利、西班牙、荷兰、土耳其和英国随访的453例肾病型胱氨酸病患者。

主要发现

  • 从1970年代至1990年代,肾脏生存期中位数增加9.1年。
  • 延迟启动胱氨酸消耗剂治疗和较高的平均白细胞胱氨酸水平与早期进展至终末期肾病显著相关。
  • 早期使用胱氨酸消耗剂和较低白细胞胱氨酸水平与线性生长显著改善相关。
  • 性别、CTNS基因致病变异、吲哚美辛或肾素-血管紧张素系统阻滞剂处方对肾功能无显著影响。

临床怎么用

  • 对肾病型胱氨酸病患者应尽早诊断并启动胱氨酸消耗剂治疗,以延缓肾功能恶化并改善生长。
  • 监测白细胞胱氨酸水平有助于评估治疗充分性和肾脏预后风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nephropathic cystinosis is a rare disease secondary to recessive mutations of the CTNS gene encoding the lysosomal cystine transporter cystinosin, causing accumulation of cystine in multiple organs. Over the years, the disease has evolved from being a fatal condition during early childhood into a treatable condition, with patients surviving into adulthood. Data on cystinosis are limited by the rarity of the disease. Here, we have investigated factors associated with kidney and growth outcome in a very large cohort of 453 patients born between 1964 and 2016 and followed in Belgium, Germany, Austria, France, Italy, Spain, The Netherlands, Turkey and United Kingdom. From the 1970s to the 1990s, the median increase in kidney survival was 9.1 years. During these years, cysteamine, a cystine-depleting agent, was introduced for the treatment of cystinosis. Significant risk factors associated with early progression to end-stage kidney disease assessed by Cox proportional multivariable analysis included delayed initiation of cysteamine therapy and higher mean leucocyte cystine levels. No significant effect on kidney function was observed for gender, pathogenic variant of the CTNS gene, and the prescription of indomethacin or renin angiotensin system blockers. Significantly improved linear growth was associated with early use of cysteamine and lower leukocyte cystine levels. Thus, our study provides strong evidence in favor of early diagnosis and optimization of cystine depletion therapy in nephropathic cystinosis.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Emma F, Hoff WV, Hohenfellner K, et al. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis. Kidney Int. 2021. PMID: 34237326. doi:10.1016/j.kint.2021.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。